Core Points - Hongri Pharmaceutical Co., Ltd. announced a self-inspection regarding tax matters, resulting in a tax payment of 25.166 million yuan and late fees of 8.6722 million yuan, totaling 33.8382 million yuan [2] - The total amount of tax and late fees paid represents approximately 43% of the company's net profit for the first half of 2025, which was 78.63 million yuan [2] - The company stated that the tax payment and late fees will be included in the 2025 current profit and loss, with the final impact on net profit to be determined by audited financial statements [2] Company Actions - The proactive self-inspection and tax payment reflect the company's commitment to compliant operations, despite the short-term pressure on performance [3] - The company aims to avoid potential risks associated with tax issues by addressing the matter promptly [3]